ACE and neoplasm: After further adjustment for comorbidities, tumor extent and primary treatment the risk association persisted for diuretics (HR 1.10, 95% CI 1.01–1.19) and ACE-inhibitors (HR 1.10, 95% CI 1.01–1.21).